Zydus gets USFDA nod to produce generic prostate cancer drug
The group now has 400 approvals and has filed over 465 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences on Saturday said it has received approval from the US health regulator to produce generic prostate cancer treatment drug.
The company has received approval from the US Food and Drug Administration (USFDA) to manufacture Enzalutamide capsules (40 mg), it said in a regulatory filing.
Enzalutamide capsules are androgen receptor inhibitors indicated for the treatment of patients with metastatic castration-resistant prostate cancer.
The drug will be produced at the group's manufacturing site in Moraiya, Ahmedabad, Zydus said.
As per IQVIA MAT July 2024 data, Enzalutamide capsules (40 mg) had annual sales of USD 869.4 million in the US.
The group now has 400 approvals and has filed over 465 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SIP Returns: You corpus can reach from Rs 2 crore to Rs 4 crore in just 3 years if you get 2 per cent additional returns; know how it can work out
Compounding Benefits: Starting Rs 5,000 SIP at 20, 25, 35? Here’s how much funds you can accumulate at retirement
SBI Senior Citizen FD Calculator: How much will you get if you invest Rs 5 lakh, Rs 10 lakh, Rs 15 lakh, or Rs 20 lakh in 1-, 3-, and 5-year fixed deposit schemes
SIP+SWP: Rs 25,000 monthly SIP investment for 20 years and then Rs 1,42,000 monthly income for 45 years; know how it is possible
07:06 PM IST